Clinical Research Directory
Browse clinical research sites, groups, and studies.
EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
Sponsor: Eisbach Bio GmbH
Summary
This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a dose escalation part (Phase 1) and a dose expansion part (Phase 2).
Official title: A Phase 1/2, Open Label Trial to Investigate the Safety, Tolerability, and Preliminary Efficacy of EIS-12656 as Single Agent and in Combination With a Poly-ADP Ribose Polymerase (PARP) Inhibitor or Trastuzumab Deruxtecan (T-DXd), an Antibody Drug Conjugate (ADC), in Participants With Specified Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
144
Start Date
2024-09-09
Completion Date
2027-12
Last Updated
2024-09-19
Healthy Volunteers
No
Interventions
EIS-12656
EIS-12656 tablets given daily
Olaparib
as per USPI/SmPC
Trastuzumab deruxtecan
as per USPI/SmPC
Locations (1)
MD Anderson Cancer Center
Houston, Texas, United States